Odonate Therapeutics, Inc. (ODT): Price and Financial Metrics

Odonate Therapeutics, Inc. (ODT): $3.21

-0.01 (-0.31%)

POWR Rating

Component Grades













ODT Stock Price Chart Interactive Chart >

Price chart for ODT

ODT Price/Volume Stats

Current price $3.21 52-week high $7.10
Prev. close $3.22 52-week low $2.80
Day low $3.10 Volume 104,565
Day high $3.23 Avg. volume 2,289,387
50-day MA $3.36 Dividend yield N/A
200-day MA $3.98 Market Cap 123.59M

Odonate Therapeutics, Inc. (ODT) Company Bio

Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

ODT Latest News Stream

Event/Time News Detail
Loading, please wait...

ODT Latest Social Stream

Loading social stream, please wait...

View Full ODT Social Stream

Latest ODT News From Around the Web

Below are the latest news stories about Odonate Therapeutics Inc that investors may wish to consider to help them evaluate ODT as an investment opportunity.

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993. Odonate Therapeutics, Inc. (NASDAQ: ODT) Accused of Misleading Investors On August 4, 2021, Judge Marilyn Huff. of the United States District Court f

Yahoo | September 8, 2021

A Odonate Therapeutics, Inc. (NASDAQ:ODT) insider increased their holdings last year

Looking at Odonate Therapeutics, Inc.'s ( NASDAQ:ODT ) insider transactions over the last year, we can see that...

Yahoo | September 6, 2021

ODONATE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Odonate Therapeutics, Inc. - ODT

NEW ORLEANS, August 21, 2021--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Odonate Therapeutics, Inc. (NasdaqGS: ODT).

Yahoo | August 21, 2021

Update in Lawsuit for Investors in Odonate Therapeutics, Inc. (NASDAQ:ODT) Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in (NASDAQ:ODT) shares.

Yahoo | August 17, 2021

Kaskela Law LLC Announces Stockholder Investigation of Odonate Therapeutics, Inc. - ODT

PHILADELPHIA, PA / ACCESSWIRE / August 16, 2021 / Kaskela Law LLC announces that it is investigating Odonate Therapeutics, Inc. ("Odonate" or the "Company") (Nasdaq:ODT).

Yahoo | August 16, 2021

Read More 'ODT' Stories Here

ODT Price Returns

1-mo 5.94%
3-mo -8.81%
6-mo -32.53%
1-year -16.51%
3-year -32.03%
5-year N/A
YTD -33.13%
2020 -40.83%
2019 130.47%
2018 -43.68%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7907 seconds.